Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients

Research output: Chapter in Book/Report/Conference proceedingConference contribution

30 Citations (Scopus)

Abstract

This article will focus on the relationship between serum levels of anti-citrullinated peptide antibodies (anti-CCP) or rheumatoid factor (RF) and clinical response to TNF-α blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti-CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease.On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre-treatment RF positivity or negativity does not influence response to TNF-α blocking therapy while high pre-treatment levels of IgA RF seem to be associated with a poor response rate.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages287-295
Number of pages9
Volume1109
DOIs
Publication statusPublished - Aug 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1109
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Rheumatoid Factor
Peptides
Antibodies
Therapeutics
Antirheumatic Agents
Immunoglobulin A
Immunoglobulin M
Anti-Idiotypic Antibodies
Antibody Formation
Rheumatoid Arthritis
Serum

Keywords

  • Anti-cyclic citrullinated peptide antibodies
  • Rheumatoid arthritis
  • Rheumatoid factor
  • Tumor necrosis factor-α inhibitors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bobbio-Pallavicini, F., Caporali, R., Alpini, C., Moratti, R., & Montecucco, C. (2007). Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients. In Annals of the New York Academy of Sciences (Vol. 1109, pp. 287-295). (Annals of the New York Academy of Sciences; Vol. 1109). https://doi.org/10.1196/annals.1398.034

Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients. / Bobbio-Pallavicini, Francesca; Caporali, Roberto; Alpini, Claudia; Moratti, Remigio; Montecucco, Carlomaurizio.

Annals of the New York Academy of Sciences. Vol. 1109 2007. p. 287-295 (Annals of the New York Academy of Sciences; Vol. 1109).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bobbio-Pallavicini, F, Caporali, R, Alpini, C, Moratti, R & Montecucco, C 2007, Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients. in Annals of the New York Academy of Sciences. vol. 1109, Annals of the New York Academy of Sciences, vol. 1109, pp. 287-295. https://doi.org/10.1196/annals.1398.034
Bobbio-Pallavicini, Francesca ; Caporali, Roberto ; Alpini, Claudia ; Moratti, Remigio ; Montecucco, Carlomaurizio. / Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients. Annals of the New York Academy of Sciences. Vol. 1109 2007. pp. 287-295 (Annals of the New York Academy of Sciences).
@inproceedings{855b04e93a7c42fbb1a824860a4c2d20,
title = "Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients",
abstract = "This article will focus on the relationship between serum levels of anti-citrullinated peptide antibodies (anti-CCP) or rheumatoid factor (RF) and clinical response to TNF-α blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti-CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease.On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre-treatment RF positivity or negativity does not influence response to TNF-α blocking therapy while high pre-treatment levels of IgA RF seem to be associated with a poor response rate.",
keywords = "Anti-cyclic citrullinated peptide antibodies, Rheumatoid arthritis, Rheumatoid factor, Tumor necrosis factor-α inhibitors",
author = "Francesca Bobbio-Pallavicini and Roberto Caporali and Claudia Alpini and Remigio Moratti and Carlomaurizio Montecucco",
year = "2007",
month = "8",
doi = "10.1196/annals.1398.034",
language = "English",
isbn = "1573316636",
volume = "1109",
series = "Annals of the New York Academy of Sciences",
pages = "287--295",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients

AU - Bobbio-Pallavicini, Francesca

AU - Caporali, Roberto

AU - Alpini, Claudia

AU - Moratti, Remigio

AU - Montecucco, Carlomaurizio

PY - 2007/8

Y1 - 2007/8

N2 - This article will focus on the relationship between serum levels of anti-citrullinated peptide antibodies (anti-CCP) or rheumatoid factor (RF) and clinical response to TNF-α blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti-CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease.On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre-treatment RF positivity or negativity does not influence response to TNF-α blocking therapy while high pre-treatment levels of IgA RF seem to be associated with a poor response rate.

AB - This article will focus on the relationship between serum levels of anti-citrullinated peptide antibodies (anti-CCP) or rheumatoid factor (RF) and clinical response to TNF-α blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti-CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease.On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre-treatment RF positivity or negativity does not influence response to TNF-α blocking therapy while high pre-treatment levels of IgA RF seem to be associated with a poor response rate.

KW - Anti-cyclic citrullinated peptide antibodies

KW - Rheumatoid arthritis

KW - Rheumatoid factor

KW - Tumor necrosis factor-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34848842839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848842839&partnerID=8YFLogxK

U2 - 10.1196/annals.1398.034

DO - 10.1196/annals.1398.034

M3 - Conference contribution

C2 - 17785317

AN - SCOPUS:34848842839

SN - 1573316636

SN - 9781573316637

VL - 1109

T3 - Annals of the New York Academy of Sciences

SP - 287

EP - 295

BT - Annals of the New York Academy of Sciences

ER -